Mark V. Pauly, For The Inquirer

Professor of Health Care Management, Business Economics and Public Policy at The Wharton School

Latest Stories

How can the U.S. reopen while limiting harm to Americans? An economics professor explains | Expert Opinion

Persons exiting home confinement potentially can harm others in the community if they carry the disease; so one obvious step would be to permit people to emerge from sheltering at home only after a negative test for current coronavirus infection.

The death rate from coronavirus is lower than we think. That’s bad news.

We want to know the true death rate both to plan public health and economic stimulus measures, and to forecast for ourselves how likely we are to die if we have not been diagnosed yet but are seeking to break out of home confinement.

What the coronavirus pandemic could mean for health insurance premiums

We should not use this extraordinary event to try to advance causes or views on the perennial problems that will be present even after it goes away.

The government should pay Americans to take coronavirus tests. Here’s why. l Opinion

People who test positive could be compensated with a lump-sum payment to fill the gap in protection against unexpected loss of wages. Plus, this policy would strongly motivate people to seek testing, helping contain the virus.

Fed up with outrageous 'surprise’ medical bills? Blame your boss. | Opinion

A key source of confusion is who has allowed this to happen? The answer: physicians, hospital systems, and private insurers who were “basically fine” with the arrangement and were unwilling to make the big concessions needed for change.

Your health insurance is making you ignore your doctor l Opinion

Out-of-pocket spending can make you decide a drug isn't worth taking, despite medical orders.

Medicare for All could bring higher wages, but not for everyone | Opinion

Economists believe that when the premium goes away, at the same salary workers become are a bargain and employers will want to hire more of them. Employers who compete to hire workers will bid up wages until they rise by the amount of the bargain — the original cost of the employer contribution.

Medicare for All and the silly season for health reform l Opinion

So what would be the social benefits and costs of wiping out current patterns of job based insurance coverage and money wages and moving to a new one?

Drug pricing reform in the U.S.: If Europeans paid more, would Americans pay less? | Opinion

The Trump administration seeks to lower US drug prices by focusing on other developed countries (think France) who, in the President’s opinion, are freeloading on American taxpayers and consumers.

Is pharma getting greedier?

There has been considerable consumer and policymaker concern about the rising prices of some prescription drugs, from the thousands-percent increases in the price of generics like Turing Pharmaceuticals' Daraprim to the average 8.8% increase by Pfizer for a large sample of its brand name drugs. Putting aside appeals by brand name firms for the need for funding for research and development (which does not apply to generics), the most attractive explanation for why brand nme drug makers can increase prices is because they can.